MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May.
The conference presentation schedule is as follows: | ||
Deutsche Bank Health Care Conference | ||
May 4, 2011 at 11:20 a.m. ET | ||
Presented by: Timothy Morris, chief financial officer | ||
InterContinental Boston, Boston, MA | ||
JMP Securities 10th Annual Research Conference | ||
May 9, 2011 at 9:00 a.m. PT | ||
Presented by: Dr. Barbara Troupin, senior director, medical affairs | ||
The Ritz-Carlton, San Francisco, CA | ||
Bank of America Merrill Lynch 2011 Health Care Conference | ||
May 11, 2011 at 4:20 p.m. PT | ||
Presented by: Peter Tam, president | ||
Encore Hotel, Las Vegas, NV | ||
UBS Global Specialty Pharmaceuticals Conference | ||
May 25, 2011 at 2:00 p.m. BST | ||
Presented by: Timothy Morris, chief financial officer | ||
UBS, One Finsbury Avenue, London, UK | ||
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: | |||
VIVUS, Inc. | Investor Relations: | The Trout Group | |
Timothy E. Morris | Brian Korb | ||
Chief Financial Officer | bkorb@troutgroup.com | ||
650-934-5200 | 646-378-2923 | ||
SOURCE VIVUS, Inc.
